On May 30, Bioanalytical Systems, Inc. (NASDAQ:BASI) announced that it hosted a workshop yesterday at UCLA designed to help academic researchers efficiently navigate the in vivo study process that is the foundation of drug discovery, lead compound optimization, and the early phases of regulated drug development. Bioanalytical Systems, Inc. (NASDAQ:BASI) net profit margin is -0.40% and weekly performance is 0.73 %. On last trading day company shares ended up $2.76. Analysts mean target price for the company is $2.15. Bioanalytical Systems, Inc. (NASDAQ:BASI) distance from 50-day simple moving average (SMA50) is 3.36%.
On May 20, Major drug development services company Covance Inc. (NYSE:CVD) in a bid to expand its market access offerings, acquired London-based value communication consultancy Medaxial. Financial terms of the deal were not disclosed. Covance Inc. (NYSE:CVD) shares advanced 1.59% in last trading session and ended the day on $84.99. Gross Margin is 27.70% and its return on assets is 7.40%. Covance Inc. (NYSE:CVD) quarterly performance is -18.44%.
Stock analysts at Raymond James began coverage on shares of PAREXEL International Corporation (NASDAQ:PRXL) in a report issued on Friday. The firm set a “market perform” rating on the stock. PAREXEL International Corporation (NASDAQ:PRXL) shares moved up 3.40% in last trading session and was closed at $51.98, while trading in range of $50.44 – $52.25. PAREXEL International Corporation (NASDAQ:PRXL) year to date (YTD) performance is 15.05%.
Thermo Fisher Scientific Inc. (NYSE:TMO) the world leader in serving science, announced that Marc N. Casper, president and chief executive officer, will present at the Goldman Sachs 35th Annual Global Healthcare Conference on Tuesday, June 10, 2014, at 11:20 a.m. (PDT) at the Terranea Resort, Rancho Palos Verdes, Calif. Thermo Fisher Scientific Inc. (NYSE:TMO) ended the last trading day at $117.88. Company weekly volatility is calculated as 1.13% and price to cash ratio as 30.88. Thermo Fisher Scientific Inc. (NYSE:TMO) showed a positive weekly performance of 2.16%.
Universal Health Services Inc (NYSE:UHS)‘s stock had its “overweight” rating reaffirmed by JPMorgan Chase & Co. in a research note issued on Tuesday. They currently have a $97.00 price objective on the stock, up from their previous price objective of $90.00. JPMorgan Chase & Co.’s price target indicates a potential upside of 7.87% from the company’s current price. Universal Health Services, Inc. (NYSE:UHS) net profit margin is 7.20% and weekly performance is 4.29%. On last trading day company shares ended up $92.83. Analysts mean target price for the company is $96.31. Universal Health Services, Inc. (NYSE:UHS) distance from 50-day simple moving average (SMA50) is 13.63%.